![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AZ Hands Over Rights of Dermatitis Candidate to LEO for Over $1B
AZ Hands Over Rights of Dermatitis Candidate to LEO for Over $1B
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
AstraZeneca is selling the rights for its atopic dermatitis candidate tralokinumab to LEO Pharma in an agreement potentially worth more than $ 1 billion.
LEO will pay $ 115 million up front for the treatment monoclonal antibody — which is currently in Phase 2 development — as well as up to $1 billion in commercially-related milestones.
Tralokinumab is also in Phase 3 development for the treatment of severe asthma, although AstraZeneca will retain the rights to tralokinumab for respiratory diseases and other indications outside of dermatology.
Upcoming Events
-
21Oct